Romiplostim
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Immune Thrombocytopenia (ITP)
Conditions
Immune Thrombocytopenia (ITP)
Trial Timeline
Sep 1, 2015 → Aug 1, 2017
NCT ID
NCT02868060About Romiplostim
Romiplostim is a phase 1/2 stage product being developed by Kyowa Kirin for Immune Thrombocytopenia (ITP). The current trial status is completed. This product is registered under clinical trial identifier NCT02868060. Target conditions include Immune Thrombocytopenia (ITP).
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04095936 | Phase 2/3 | Completed |
| NCT03957694 | Phase 2/3 | Completed |
| NCT02773290 | Phase 2/3 | Completed |
| NCT02868060 | Phase 1/2 | Completed |
Competing Products
20 competing products in Immune Thrombocytopenia (ITP)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pirtobrutinib + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Anti-(integrin beta-3) human monoclonal antibody | Rallybio | Phase 2 | 44 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Placebo + Lusutrombopag | Shionogi | Phase 2 | 52 |
| Lusutrombopag | Shionogi | Phase 2 | 52 |
| AMG 531 | Kyowa Kirin | Phase 2/3 | 65 |
| Romiplostim + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Romiplostim (AMG-531) | Kyowa Kirin | Phase 2 | 52 |
| Romiplostim and danazol | Kyowa Kirin | Phase 2 | 52 |
| Hetrombopag Olamine | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR0302 quick release tablets + SHR0302 sustained-release tablets | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Hetrombopag + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| HR19042 Capsule, Tarpeyo®, Budenofalk® | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| HR19042 Capsules | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Herombopag | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Zostavax® | Merck | Pre-clinical | 23 |
| Raltegravir + Atazanavir | Merck | Pre-clinical | 23 |
| Zostavax | Merck | Pre-clinical | 23 |
| MK-8723 + Matching Placebo | Merck | Phase 1 | 33 |
| Eltrombopag (Revolade®) + standard therapy (without eltrombopag): HD-DXM | Novartis | Phase 2 | 52 |